The effects of T-cell subsets by HMAs for three relapsed AML patients post-allo-HSCT has been reported: HMAs increased the populations of CD4+CD25+FOXP3+ regulatory T-cells (also confirmed as CD4+CD25hiCD127lo T-cells); HMAs also decreased CD8+ T-cells and Th1 cells, decreased CD8+ cytotoxicity, decreased IFN-γ production, and increased the transcription of IL-10 and TGF-β cytokines (Stübig et al., 2014). The gene discussed is CD8A; the disease is acute myeloid leukemia.